Tags : (aclidinium)

Circassia Plans to Exercise Option for the US Commercialization Rights

Vartika Singh December 12, 2018

Shots: AstraZeneca (AZ) will receive $5M option license fee and additional $20M on approval of Duaklir (aclidinium / formoterol) (product of AZ) from Circassia. Circassia to get US commercialization rights […]readmore

Tags : (aclidinium)

Circassia Plans to Exercise Option for the US Commercialization Rights

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : (aclidinium)

Circassia Plans to Exercise Option for the US Commercialization Rights

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company